Neurophysiologic follow-up of long-term dietary treatment in adult- onset adrenoleukodystrophy

Neurology

Volumn 52, Issue 4, 1999, Pages 810-816

  Restuccia, D ^a   Di Lazzaro, V ^b   Valeriani, M ^b   Oliviero, A ^b   Le Pera, D ^b   Barba, C ^b   Cappa, M ^b   Bertini, E ^b   Di Capua, M ^b   Tonali, P ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LORENZO OIL;

ADRENOLEUKODYSTROPHY; ARTICLE; CLINICAL ARTICLE; DETERIORATION; DIET THERAPY; DISEASE SEVERITY; EVOKED MUSCLE RESPONSE; EVOKED SOMATOSENSORY RESPONSE; FOLLOW UP; HUMAN; LOW FAT DIET; NEUROPHYSIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL;

EID: 0033541086     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.4.810     Document Type: Article

References (37)

1. Moser HW, Moser AB. Adrenoleukodystrophy (X-linked). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited diseases. New York: McGraw-Hill, 1989: 1511-1532.
2. Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997;120:1485-1508. Review.
3. Edwin D, Speedie LJ, Konzer W, Naidu S, Kruse B, Moser HW. Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy. Ann Neurol 1996;40:675-678.
4. Kumar AJ, Köhler W, Kruse B, et al. MR findings in adult-onset adrenoleukodystrophy. AJNR Am J Neuroradiol 1995; 16:1227-1237.
5. Rizzo WB, Leshner RT, Odone A, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989; 39:1415-1422.
6. Moser HW, Tutschka PJ, Brown FR, et al. Bone marrow transplant in adrenoleukodystrophy. Neurology 1984;34: 1410-1417.
7. Stumpf DA, Hayward A, Haas R, Frost M, Schaumburg HH. Adrenoleukodystrophy. Failure of immunosuppression to prevent neurological progression. Arch Neurol 1981;38:48-49.
8. Oka A, Saito M, Kubota M, Sakakihara Y, Yanigisawa M. Temporary improvement of neurological symptoms with gammaglobulin therapy in a boy with adrenoleukodystrophy. Brain Dev 1996;18:119-121.
9. Rizzo WB. Lorenzo's oil. Hope and disappointment. N Engl J Med 1993;329:801-802. Editorial.
10. Uziel G, Bertini E, Rimoldi M, Gambetti M. Italian multicentric dietary therapeutical trial in adrenoleukodystrophy. In: Uziel G, Wanders RJA, Cappa M, eds. Adrenoleukodystrophy and other peroxisomal disorders. Excerpta Medica International Congress Series. Amsterdam: 1990:163-180.
11. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. A two-year trial of oleic and erucic acids (Lorenzo's oil) as treatment for adrenomyeloneuropathy. N Engl J Med 1993;11:745-752.
12. Kaplan PW, Tusa RJ, Shankroff J, Heller JE, Moser HW. Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann Neurol 1993;34: 169-174.
13. Poulos A, Gibson R, Sharp P, Beckmann K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil. Ann Neurol 1994;36: 741-746.
14. Rasmussen M, Moser AB, Borel J, Khangoora S, Moser HW. Brain, liver and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceril trierucate and trioleate oils (Lorenzo's oil). Neurochem Res 1994;19:1073-1082.
15. Moser HW. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995;54:740-745.
16. Garg BP, Markand ON, DeMyer WE, Warren C. Evoked response studies in patients with adrenoleukodystrophy and heterozygous relatives. Arch Neurol 1983;40:356-359.
17. Tobimatsu S, Fukui R, Kato M, Kobayashi T, Kuroiwa Y. Multimodality evoked potentials in patients and carriers with adrenoleukodystrophy and adrenomyeloneuropathy. Electroencephalogr Clin Neurophysiol 1985;62:18-24.
18. Kukowski B. Magnetic transcranial brain stimulation and multimodality evoked potentials in an adrenoleukodystrophy patient and members of his family. Electroencephalogr Clin Neurophysiol 1991;78:260-262.
19. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. Brain MRI and electrophysiologic abnormalities in preclinical and clinical adrenomyeloneuropathy. Neurology 1992;42:85-91.
20. Restuccia D, Di Lazzaro V, Valeriani M, et al. Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement. Brain 1997;120:1139-1148.
21. Di Biase A, Salvati S, Quaresima T, Pieroni F, Grisolia A, Cambiaso P. C24:0/C22:0 ratio in plasma sphingomyelin as a practical tool for the diagnosis of adrenoleukodystrophy and adrenomyeloneuropathy. Clin Chem Enzym Comms 1995;7: 35-40.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis; an expanded disability status scale (EDSS). Neurology 1983;33:1449-1452.
23. Restuccia D, Valeriani M, Di Lazzaro V, Tonali P, Mauguière F. Somatosensory evoked potentials after multisegmental upper limb stimulation in diagnosis of cervical spondylotic myelopathy. J Neurol Neurosurg Psychiatry 1994;57:301-308.
24. Restuccia D, Di Lazzaro V, Valeriani M, Colosimo C, Tonali P. N24 spinal response to tibial nerve stimulation and magnetic resonance imaging in lesions of the lumbosacral spinal cord. Neurology 1993,-43:2269-2275.
25. Desmedt JE, Cheron G. Central somatosensory conduction in man: neural generators and interpeak latencies of far-field components recorded from neck and right or left scalp and earlobes. Electroencephalogr Clin Neurophysiol 1980;50:382-403.
26. Yamada T, Ishida T, Kudo Y, Rodnitzky RL, Kimura J. Clinical correlates of abnormal P14 in median SEPs. Neurology 1986;36:765-771.
27. Restuccia D, Mauguière F. The contribution of median nerve SEPs in the functional assessment of the cervical spinal cord in syringomyelia. A study of 24 patients. Brain 1991;114:361-379.
28. Garcia-Larrea L, Mauguière F. Latency and amplitude abnormalities of the scalp far-field P14 to median nerve stimulation in multiple sclerosis. A SEP study of 122 patients recorded with a non-cephalic reference montage. Electroencephalogr Clin Neurophysiol 1988;71:180-186.
29. Di Lazzaro V, Restuccia D, Colosimo C, Tonali P. The contribution of magnetic stimulation of the motor cortex to the diagnosis of cervical spondylotic myelopathy. Correlation of central motor conduction to distal and proximal upper limb muscles with clinical and MRI findings. Electroencephalogr Clin Neurophysiol 1992;85:311-320.
30. Moser HW, Moser AB, Naidu S, Bergin A. Clinical aspects of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:254-261. Review.
31. Moser HW, Aubourg P, Cornblath D, et al. Therapy for X-linked adrenoleukodystrophy. In: Desnick RJ, ed. Treatment of genetic diseases. New York: Churchill Livingstone, 1991:111-129.
32. Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992;51:630-643.
33. Schaumburg HH, Powers JM, Raine CS, et al. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. II. General pathologic, neuropathologic and biochemical aspects. Neurology 1977;27:1114-1119.
34. Powers JM. The pathology of peroxisomal disorders with pathogenetic considerations. J Neuropathol Exp Neurol 1995; 54:710-719.
35. Chaudry V, Moser HW, Cornblath DR. Nerve conduction studies in adrenomyeloneuropathy. J Neurol Neurosurg Psychiatry 1996;61:181-185.
36. Mauguière F, Desmedt JE, Courjon J. Neural generators of N18 and P14 far-field somatosensory evoked potentials studied in patients with lesion of thalamus or thalamo-cortical radiations. Electroencephalogr Clin Neurophysiol 1983;56: 283-292.
37. Restuccia D, Di Lazzaro V, Valeriani M, et al. Abnormalities of somatosensory and motor evoked potentials in adrenomyeloneuropathy: comparison with magnetic resonance imaging and clinical findings. Muscle Nerve 1997;20: 1249-1257.